Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
SOURCE Decision Resources
Approval of Premium-Priced Novel Agents, Coupled With Rituximab's Continued Dominance, Will Drive a Robust Annual Growth, According to a New Report from Decision Resources
BURLINGTON, Mass., Oct. 28, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, from 2012 to 2022, the launch of five premium-priced new agents-Johnson & Johnson/Janssen/Pharmacyclics' ibrutinib, Gilead Sciences' idelalisib, Roche/Genentech/Chugai/Glycart's obinutuzumab, Celgene's Revlimid and Pfizer's Afinitor-together with the continued use of rituximab (Roche/Genentech/Chugai Seiyaku/Zenyaku Kogyo's Rituxan/MabThera) will fuel more than 6 percent annual growth in the non-Hodgkin's lymphoma (NHL) drug market. In the United States, France, Germany, Italy, Spain, the United Kingdom and Japan, sales will exceed $10 billion in 2022, with the kinase inhibitors ibrutinib and idelalisib comprising more than one-fifth of market share. These two agents will launch as treatments for multiple NHL subpopulations, and their use in combination with existing therapies, as well as monotherapies, will ensure that they will significantly add to the overall size of the market. The anticipated approval of Revlimid in the diffuse large B-cell lymphoma maintenance setting will also trigger significant market growth.
The Pharmacor advisory service entitled Non-Hodgkin's Lymphoma finds that sales of rituximab dominate the current market, and will continue to do so through 2022, regardless of biosimilar rituximab entry. Teva Pharmaceutical Industries' Treanda/Levact/Treakisym/Ribomustin, a cytotoxic chemotherapy that is becoming more and more entrenched in the treatment of NHL, will continue to experience an increase in use across most NHL subpopulations, but its sales will decline as a result of generic entry.
"New therapies entering the market will change the way NHL patients are treated by 2022," said Decision Resources Business Insights Analyst Dana Gheorghe, Ph.D. "Of particular interest are the entries of the kinase inhibitors ibrutinib and idelalisib, which are poised to have a tremendous impact on the treatment of NHL patients, especially those with relapsed/refractory chronic lymphocytic leukemia and follicular lymphoma, but also mantle cell lymphoma. The anticipated approval of obinutuzumab will also impact how some NHL patients are managed, as the drug has been shown to be more efficacious than rituximab in certain subpopulations."
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.
About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
©2012 PR Newswire. All Rights Reserved.